Copyright
©The Author(s) 2015.
World J Methodol. Jun 26, 2015; 5(2): 101-107
Published online Jun 26, 2015. doi: 10.5662/wjm.v5.i2.101
Published online Jun 26, 2015. doi: 10.5662/wjm.v5.i2.101
Standard triple therapy (7-14 d) | PPI - standard dose, bid Clarithromycin - 500 mg, bid Amoxicillin - 1 g, bid |
Bismuth quadruple Therapy (10-14 d) | PPI - standard dose, bid Bismuth - standard dose, qid Tetracycline - 500 mg, qid Metronidazole - 500 mg, tid |
Sequential therapy (5-d dual therapy followed by a 5-d triple therapy) | Dual therapy; PPI - standard dose, bid Amoxicillin - 1 g, bid Triple therapy; PPI - standard dose, bid Clarithromycin - 500 mg, bid Metronidazole - 500 mg, bid |
Concomitant therapy (7-10 d) | PPI - standard dose, bid Clarithromycin - 500 mg, bid Amoxicillin - 1 g, bid Metronidazole - 500 mg, bid |
Hybrid therapy (7-d dual therapy followed by a 7-d quadruple therapy) | Dual therapy; PPI - standard dose, bid |
Amoxicillin - 1 g, bid | |
Triple therapy; PPI - standard dose, bid | |
Amoxicillin - 1 g, bid | |
Clarithromycin - 500 mg, bid | |
Metronidazole - 500 mg, bid | |
Levofloxacin-based triple therapy (10-d) | PPI - standard dose, bid |
Levofloxacin - 500 mg, qd | |
Amoxicillin - 1 g, bid | |
Rifabutin-based triple therapy (7-14 d) | PPI - standard dose, bid |
Amoxicillin - 1 g, bid | |
Rifabutin - 150 mg, qd | |
Culture-guided therapy (10-d) | PPI - standard dose, bid |
Bismuth - standard dose, qid | |
Two antibiotics selected by antimicrobial sensitivity tests |
-
Citation: Ermis F, Tasci ES. Current
Helicobacter pylori treatment in 2014. World J Methodol 2015; 5(2): 101-107 - URL: https://www.wjgnet.com/2222-0682/full/v5/i2/101.htm
- DOI: https://dx.doi.org/10.5662/wjm.v5.i2.101